利法西明α的使用与肝硬化患者的肌肉质量改善有关
Thomas Worland1, Penelope Hey2,3, Darren Wong3,4
1Department of Gastroenterology, Monash Health, Clayton 3168, Victoria, Australia. thomas.worland@monashhealth.org.
利法西明-α疗法可以改善肝硬化和肝脏脑病变 (HE) 患者的肌肉质量. 这项研究发现,rifaximin-α和骨肌面积增加 (SMA) 在这个患者组之间存在独立的关联.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 胃肠病学 胃肠病学
- 肌肉生理学 肌肉生理学
背景情况:
- 在肝硬化患者中,萨尔科佩尼亚显著增加了死亡率,无论肝病的严重程度如何.
- 除了营养支持之外,肝硬化相关的肉症的治疗选择有限.
研究的目的:
- 评估肝脏脑病 (HE) 的抗微生物药物利法西明-α是否可以改善肝硬化症中的肉类.
- 通过减少氨和抗炎作用,研究利法西明-α的潜在益处.
主要方法:
- 追溯队列研究比较乳糖单独与乳糖加利法西明-α在患者之前的HE.
- 主要结局:通过CT扫描改变骨肌肉区域 (SMA).
- 二次结局:自发的细菌性周周炎,水出血和Clostridium difficile感染.
主要成果:
- 多变量分析显示,利法西明α的使用独立地与改善的SMA有关 (P=0.029).
- 在单变量分析中,男性性别,肝细胞癌和更高的BMI与SMA改善有关.
- 包括142名患者:63名接受利法西明-α,79名仅接受乳糖治疗.
结论:
- 利法西明-α疗法在肝硬化患者的肌肉质量改善方面显示出显著的独立关联.
- 需要进一步的前性研究来证实rifaximin-α在这种队列中对萨尔科佩尼亚的治疗作用.
更多相关视频
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
05:41Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
